Atrium Therapeutics, Inc. (RNA) Key Metrics
RNA valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $131.2M
- Enterprise value
- −$119.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 3.7
- Price / book
- 0.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.93
RNA key metrics, 2012–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRNA returns How much profit the business earns on the capital it uses.
Return on equity+24.1 pts
−9.4%
2025 · hover or tap a bar for each year
20122025
Return on assets+21.1 pts
−8.3%
2025 · hover or tap a bar for each year
20122025
Free cash flow margin
−228.7%
2025 · hover or tap a bar for each year
20122025
Asset turnover+103.3%
0.02
2025 · hover or tap a bar for each year
20122025
RNA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$1.09
2025 · hover or tap a bar for each year
20122025
Earnings per share
−$4.48
2025 · hover or tap a bar for each year
20122025
Free cash flow per share
−$2.49
2025 · hover or tap a bar for each year
20122025
Book value per share
$12.11
2025 · hover or tap a bar for each year
20122025
Shares outstanding
17.1M
2025 · hover or tap a bar for each year
20122025
RNA financial health Debt, liquidity and how easily interest is covered.
Debt / equity+271.2%
0.02
2025 · hover or tap a bar for each year
20122025
Net debt+$1.2B
−$266.3M
2025 · hover or tap a bar for each year
20122025
Current ratio−58.5%
6.53
2025 · hover or tap a bar for each year
20122025
Debt / assets+203.3%
0.01
2025 · hover or tap a bar for each year
20122025
RNA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−218 days
399 days
2025 · hover or tap a bar for each year
20122025
Days payables outstanding−570 days
565 days
2025 · hover or tap a bar for each year
20122025
Cash conversion cycle+352 days
-167 days
2025 · hover or tap a bar for each year
20122025
Capex / revenue−57.1 pts
7.8%
2025 · hover or tap a bar for each year
20122025
RNA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RNA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RNA cash returned to shareholders
DividendsBuybacksFree cash flow
RNA key metrics
2012–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Per share | ||||||||||
| Revenue per share | $1.09 | — | $0.13 | $0.18 | $0.23 | $0.31 | $0.06 | $0.02 | — | — |
| Earnings per share | −$4.48 | — | −$2.91 | −$3.24 | −$2.83 | −$2.03 | −$0.66 | −$0.58 | — | — |
| Operating cash flow per share | −$2.40 | — | −$1.63 | −$2.61 | −$2.29 | −$1.71 | $0.07 | −$0.47 | — | — |
| Free cash flow per share | −$2.49 | — | −$1.69 | −$2.67 | −$2.38 | −$1.76 | $0.06 | −$0.47 | — | — |
| Cash per share | $15.78 | — | $8.15 | $11.71 | $9.79 | $15.15 | $2.52 | $0.15 | — | — |
| Book value per share | $12.11 | — | $6.86 | $11.08 | $9.21 | $14.14 | −$1.74 | −$1.99 | — | — |
| Tangible book value per share | $12.11 | — | $6.86 | $11.08 | $9.21 | $14.14 | −$1.74 | −$1.99 | — | — |
| Dividends per share | — | — | — | — | $0.00 | $0.02 | $0.00 | $0.01 | — | — |
| Capex per share | $0.08 | — | $0.06 | $0.05 | $0.09 | $0.05 | $0.01 | $0.00 | — | — |
| Debt per share | $0.21 | — | $0.13 | $0.20 | $0.28 | $0.04 | $0.13 | $0.50 | — | — |
| Shares outstanding | 17.1M | — | 73.0M | 52.2M | 41.4M | 21.7M | 37.5M | 20.7M | — | — |
| Change in shares outstanding | — | — | +40.0% | +25.9% | +91.2% | −42.2% | +81.4% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −9.4% | −33.5% | −39.3% | −35.2% | −34.1% | −36.5% | — | — | — | — |
| Return on assets (ROA) | −8.3% | −29.4% | −33.5% | −31.7% | −30.8% | −20.4% | −49.0% | −18.5% | — | — |
| Return on tangible assets | −27.5% | −20.6% | −33.8% | −26.5% | −27.4% | −13.2% | −25.5% | −299.7% | — | — |
| Free cash flow margin | −228.7% | — | — | — | — | −563.0% | 97.2% | — | — | — |
| Financial health | ||||||||||
| Total debt | $3.7M | $6.8M | $9.9M | $10.7M | $11.7M | $938,000 | $4.9M | $10.3M | $10.5M | $8.2M |
| Cash & short-term investments | $270.0M | $1.50B | $595.4M | $610.7M | $405.5M | $328.1M | $94.6M | $3.1M | $113.3M | $53.7M |
| Net debt | −$266.3M | −$1.49B | −$585.5M | −$600.0M | −$393.8M | −$327.2M | −$89.6M | $7.2M | −$102.8M | −$45.5M |
| Debt / equity | 0.02 | 0.00 | 0.02 | 0.02 | 0.03 | 0.00 | — | — | 0.12 | 0.40 |
| Debt / assets | 0.01 | 0.00 | 0.02 | 0.02 | 0.03 | 0.00 | 0.05 | 2.59 | 0.08 | 0.13 |
| Current ratio | 6.53 | 15.73 | 7.58 | 12.00 | 13.86 | 22.74 | 9.35 | 0.70 | — | — |
| Quick ratio | 6.53 | 15.73 | 7.67 | 12.00 | 13.89 | 22.82 | 9.35 | 0.70 | — | — |
| Interest coverage | — | — | — | -31.4 | -184.7 | -211.9 | -2.3 | -14.6 | — | — |
| Working capital | $231.0M | $1.44B | $530.6M | $571.0M | $381.5M | $317.1M | $85.4M | −$1.4M | — | — |
| Invested capital | −$59.0M | −$69.7M | −$84.7M | −$22.0M | −$12.4M | −$21.0M | −$155.0M | −$33.9M | −$15.7M | −$25.0M |
| Tangible asset value | $207.3M | $1.42B | $500.8M | $578.1M | $381.4M | $306.2M | −$65.4M | −$41.1M | $86.1M | $19.4M |
| Net current asset value | $201.8M | $1.40B | $483.5M | $562.2M | $365.0M | $304.0M | −$66.6M | −$41.9M | — | — |
| Graham net-net per share | $12.17 | — | $6.44 | $10.60 | $8.68 | $13.88 | −$1.79 | −$2.03 | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $0 | $444,000 | $106,000 | $106,000 | — | — |
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $0 | — | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | 4.7% | — | — | — |
| Capex / revenue | 7.8% | 64.8% | 44.2% | 30.6% | 40.1% | 16.1% | 10.1% | 12.9% | 6.4% | 3.0% |
| Capex / operating cash flow | — | — | — | — | — | — | 9.4% | — | — | — |
| Capex / depreciation | 4.47 | 2.55 | 2.01 | 2.04 | 5.85 | 2.93 | 0.68 | 0.13 | — | — |
| Stock-based compensation / revenue | 41.2% | 471.3% | 399.8% | 294.2% | 182.9% | 63.5% | 17.5% | 15.8% | — | — |
| R&D / revenue | 288.7% | 2,786.0% | 1,997.6% | 1,630.6% | 1,084.9% | 554.0% | 627.0% | 2,225.9% | 194.3% | 183.3% |
| SG&A / revenue | 223.8% | 791.4% | 588.8% | 409.1% | 280.9% | 198.3% | 220.4% | 644.1% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 398.6 | 617.1 | 238.6 | 94.5 | 41.1 | 53.8 | 125.9 | — | — | — |
| Days of inventory on hand | — | — | -637.0 | -118.4 | -599.8 | -5.8 | 0.0 | — | — | — |
| Days payables outstanding | 565.3 | 1,135.4 | 1,168.0 | 979.3 | 3,013.4 | 48.8 | 48.6 | 90.8 | 32.5 | 51.6 |
| Cash conversion cycle (days) | -166.8 | -518.3 | -1,566.3 | -1,003.3 | -3,572.1 | -0.8 | 77.3 | — | — | — |
| Receivables turnover | 0.92 | 0.59 | 1.53 | 3.86 | 8.88 | 6.79 | 2.90 | — | — | — |
| Payables turnover | 0.65 | 0.32 | 0.31 | 0.37 | 0.12 | 7.48 | 7.51 | 4.02 | 11.24 | 7.08 |
| Inventory turnover | — | — | — | — | — | — | 14,539,000.00 | — | — | — |
| Asset turnover | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | 0.05 | 0.01 | 0.14 | 0.22 |
| Average receivables | $20.3M | $18.4M | $6.2M | $2.4M | $1.1M | $1.0M | $800,000 | — | — | — |
| Average payables | $6.4M | $8.6M | $6.7M | $3.7M | $5.3M | $5.0M | $1.9M | $2.1M | $2.9M | $3.2M |
| Average inventory | — | — | −$3.7M | −$450,000 | −$1.1M | −$600,000 | $1 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 1.8% |
Computed from RNA's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RNA valuation and financial ratios
Atrium Therapeutics earned a return on equity of −9.4% in fiscal 2025. It ended the year with $3.7 million of debt and $270.0 million in cash and short-term investments, a net cash position of $266.3 million.
See the RNA income statement, the RNA chart for price history, or the RNA stock overview for the latest quote and news.
RNA key metrics FAQ
What is Atrium Therapeutics's return on equity?
Atrium Therapeutics's return on equity (ROE) was −9.4% in fiscal 2025: net income of -$76.7 million on average shareholders' equity of $816.1 million.
How much debt does Atrium Therapeutics have?
Atrium Therapeutics had total debt of $3.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Atrium Therapeutics's current ratio?
Atrium Therapeutics's current ratio was 6.53 at the end of fiscal 2025: current assets were 6.53 times current liabilities.